Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Vultaggio A, Azzari C, Ricci S, Martire B, Palladino V, Gallo V, Pecoraro A, Pignata C, Spadaro G, Graziani S, Moschese V, Trizzino A, Boggia GM, Matucci A.

J Clin Immunol. 2018 Jun 28. doi: 10.1007/s10875-018-0528-5. [Epub ahead of print]

PMID:
29951948
2.

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.

Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, Nencini F, Pratesi S, Maggi E, Vultaggio A.

Front Immunol. 2018 May 29;9:1198. doi: 10.3389/fimmu.2018.01198. eCollection 2018.

3.

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

Matucci A, Vultaggio A, Maggi E, Kasujee I.

Respir Res. 2018 Jun 8;19(1):113. doi: 10.1186/s12931-018-0813-0. Review.

4.

IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution.

Vultaggio A, Nencini F, Carraresi A, Pratesi S, Movérare R, Eriksson C, Venemalm L, Maggi E, Matucci A.

Allergy. 2018 May 2. doi: 10.1111/all.13471. [Epub ahead of print]

PMID:
29719053
5.

The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.

Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, Matucci A.

J Allergy Clin Immunol Pract. 2018 Apr 13. pii: S2213-2198(18)30278-2. doi: 10.1016/j.jaip.2018.04.007. [Epub ahead of print]

PMID:
29660428
6.

Factors reducing omalizumab response in severe asthma.

Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, Cresti A, Santus P, Perrella A, Paggiaro PL.

Eur J Intern Med. 2018 Jun;52:78-85. doi: 10.1016/j.ejim.2018.01.026. Epub 2018 Feb 1.

PMID:
29395935
7.

Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.

Vitiello G, Orsi Battaglini C, Carli G, Radice A, Matucci A, Vultaggio A, Olianti C, Parronchi P, Maggi E, Cammelli D.

Angiology. 2018 Jan 1:3319717753223. doi: 10.1177/0003319717753223. [Epub ahead of print]

PMID:
29343075
8.

Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.

Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, Cresti A, Paggiaro PL.

J Investig Allergol Clin Immunol. 2017;27(6):388-391. doi: 10.18176/jiaci.0196. No abstract available.

9.

Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42].

Spadaro G, Vultaggio A, Bosi A, Reichert D, Janssen J, Lamacchia D, Nappi L, Pecoraro A, Milito C, Ferraro A, Matucci A, Bacchiarri F, Carrai V, Hibbeler A, Speckman E, Guarnieri C, Bongiovanni S, Quinti I.

Int Immunopharmacol. 2018 Apr;57:201. doi: 10.1016/j.intimp.2017.10.014. Epub 2017 Oct 28. No abstract available.

PMID:
29089244
10.

IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients.

Vultaggio A, Nencini F, Pratesi S, Cammelli D, Totaro M, Romagnani S, Maggi E, Matucci A; ABIRISK Consortium.

J Immunol. 2017 Aug 15;199(4):1283-1289. doi: 10.4049/jimmunol.1700008. Epub 2017 Jul 17.

PMID:
28716826
11.

Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case.

Innocenti A, Innocenti M, Taverna C, Melita D, Mori F, Ciancio F, De Giorgi V, Parronchi P, Vultaggio A, Matucci A.

Int J Surg Case Rep. 2017;31:241-244. doi: 10.1016/j.ijscr.2017.01.062. Epub 2017 Jan 30.

12.

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.

Spadaro G, Vultaggio A, Alberto Bosi A, Reichert D, Janssen J, Lamacchia D, Nappi L, Pecoraro A, Milito C, Ferraro A, Matucci A, Bacchiarri F, Carrai V, Hibbeler A, Speckman E, Guarnieri C, Bongiovanni S, Quinti I.

Int Immunopharmacol. 2017 Mar;44:38-42. doi: 10.1016/j.intimp.2016.12.030. Epub 2017 Jan 7. Erratum in: Int Immunopharmacol. 2018 Apr;57:201.

PMID:
28073042
13.

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Canessa C, Iacopelli J, Pecoraro A, Spadaro G, Matucci A, Milito C, Vultaggio A, Agostini C, Cinetto F, Danieli MG, Gambini S, Marasco C, Trizzino A, Vacca A, De Mattia D, Martire B, Plebani A, Di Gioacchino M, Gatta A, Finocchi A, Licciardi F, Martino S, De Carli M, Moschese V, Azzari C.

Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7.

14.

Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.

Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A.

Expert Opin Drug Saf. 2016 Dec;15(sup1):3-10. Review.

PMID:
27924646
15.

An overview on safety of monoclonal antibodies.

Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A.

Curr Opin Allergy Clin Immunol. 2016 Dec;16(6):576-581. Review.

PMID:
27749360
16.

Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.

Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Milla M, Prignano F, Annese V, Romagnani S, Maggi E, Matucci A; ABIRISK Consortium.

Clin Exp Immunol. 2016 Dec;186(3):364-372. doi: 10.1111/cei.12858. Epub 2016 Oct 26.

17.

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.

Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, Masieri S, Rolla G, Steinhilber G, Rosati Y, Vultaggio A, Folletti I, Baglioni S, Bargagli E, Di Tomassi M, Pio R, Pio A, Maccari U, Maggiorelli C, Migliorini MG, Vignale L, Pulerà N, Carpagnano GE, Foschino Barbaro MP, Perrella A, Paggiaro PL.

Respir Med. 2016 Oct;119:141-149. doi: 10.1016/j.rmed.2016.09.005. Epub 2016 Sep 4.

18.

How the immune system responds to therapeutic biological agents.

Vultaggio A, Petroni G, Pratesi S, Nencini F, Cammelli D, Ferraro A, Maggi E, Matucci A.

J Int Med Res. 2016 Sep;44(1 suppl):38-42.

19.

Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity.

Pratesi S, Nencini F, Filì L, Occhiato EG, Romagnani S, Parronchi P, Maggi E, Vultaggio A.

Mol Immunol. 2016 Sep;77:60-70. doi: 10.1016/j.molimm.2016.07.011. Epub 2016 Jul 29.

PMID:
27475304
20.

The safety of monoclonal antibodies in asthma.

Passalacqua G, Matucci A, Vultaggio A, Bagnasco D, Mincarini M, Maggi E, Canonica GW.

Expert Opin Drug Saf. 2016 Aug;15(8):1087-95. doi: 10.1080/14740338.2016.1186641. Review.

PMID:
27215447
21.

In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.

Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, Vultaggio A, Brockow K, Caubet JC, Makowska J, Nakonechna A, Romano A, Montañez MI, Laguna JJ, Zanoni G, Gueant JL, Oude Elberink H, Fernandez J, Viel S, Demoly P, Torres MJ; In vitro tests for Drug Allergy Task Force of EAACI Drug Interest Group.

Allergy. 2016 Aug;71(8):1103-34. doi: 10.1111/all.12886. Epub 2016 May 25.

PMID:
26991315
22.

Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly.

Scichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Caminati M, Del Giacco S, Heffler E, Lombardi C, Matucci A, Milanese M, Paganelli R, Passalacqua G, Patella V, Ridolo E, Rolla G, Rossi O, Schiavino D, Senna G, Steinhilber G, Vultaggio A, Canonica G.

Clin Mol Allergy. 2015 Jun 22;13(1):7. doi: 10.1186/s12948-015-0016-x. eCollection 2015.

23.

Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation.

Nencini F, Pratesi S, Petroni G, Filì L, Cardilicchia E, Casini A, Occhiato EG, Calosi L, Bani D, Romagnani S, Maggi E, Parronchi P, Vultaggio A.

Immunology. 2015 Aug;145(4):570-82. doi: 10.1111/imm.12475. Epub 2015 Jun 8.

24.

High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics.

Vultaggio A, Virgili G, Gaeta F, Romano A, Maggi E, Matucci A.

PLoS One. 2015 Apr 16;10(4):e0121857. doi: 10.1371/journal.pone.0121857. eCollection 2015.

25.

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.

Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A, Eiwegger T, Firinu D, Harr T, Knol E, Matucci A, Palomares O, Schmidt-Weber C, Simon HU, Steiner UC, Vultaggio A, Akdis CA, Spertini F.

Allergy. 2015 Jul;70(7):727-54. doi: 10.1111/all.12616. Epub 2015 Apr 24. Review.

PMID:
25819018
26.

Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.

Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, Trizzino A, Baldassarre M, Paganelli R, Moschese V, Soresina A, Matucci A.

Clin Drug Investig. 2015 Mar;35(3):179-85. doi: 10.1007/s40261-015-0270-1.

27.

Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects.

Matucci A, Maggi E, Vultaggio A.

Front Immunol. 2015 Jan 12;5:690. doi: 10.3389/fimmu.2014.00690. eCollection 2014. Review.

28.

Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions.

Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A.

J Interferon Cytokine Res. 2014 Dec;34(12):946-952.

PMID:
25493962
29.

Assays and strategies for immunogenicity assessment of biological agents.

Nencini F, Pratesi S, Petroni G, Matucci A, Maggi E, Vultaggio A.

Drug Dev Res. 2014 Nov;75 Suppl 1:S4-6. doi: 10.1002/ddr.21184. Review.

PMID:
25381974
30.

Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.

Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, Matucci A, Macchia L, Vianello A, Vultaggio A, Celi A, Cazzola M, Paggiaro P; Xolair Italian Study Group.

Pulm Pharmacol Ther. 2015 Apr;31:123-9. doi: 10.1016/j.pupt.2014.09.007. Epub 2014 Sep 30.

PMID:
25281265
31.

Hypersensitivity reactions to biologic agents.

Vultaggio A, Castells MC.

Immunol Allergy Clin North Am. 2014 Aug;34(3):615-32, ix. doi: 10.1016/j.iac.2014.04.008. Review.

PMID:
25017680
32.

Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents.

Matucci A, Maggi E, Vultaggio A.

J Rheumatol Suppl. 2014 May;91:17-23. doi: 10.3899/jrheum.140098. Review.

PMID:
24788996
33.

Hapten-specific TH17 cells in the peripheral blood of β-lactam-induced AGEP.

Filì L, Cardilicchia E, Severino MG, Testi S, Matucci A, Vultaggio A, Paglierani M, Massi D, Maggi E, Parronchi P.

Allergol Int. 2014 Mar;63(1):129-31. doi: 10.2332/allergolint.13-LE-0582. Epub 2013 Dec 25. No abstract available.

34.

Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.

Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, Maggi E, Vultaggio A.

Clin Exp Allergy. 2013 Jun;43(6):659-64. doi: 10.1111/cea.12098.

PMID:
23711128
35.

A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy.

Filì L, Vultaggio A, Cardilicchia E, Manuelli C, Casini A, Nencini F, Maggi L, Pratesi S, Petroni G, Boscaro F, Guarna A, Occhiato EG, Romagnani S, Maggi E, Parronchi P.

J Allergy Clin Immunol. 2013 Jul;132(1):84-92. doi: 10.1016/j.jaci.2013.01.030. Epub 2013 Mar 14.

PMID:
23498597
36.

The management of paediatric allergy: not everybody's cup of tea--10-11th February 2012.

Fiocchi A, Annunziato F, Assa'ad A, Arshad H, Bahna SL, Boyle R, Brozek J, Bush A, Canonica W, Cicardi M, Compalati E, Dahdah L, Dupont C, Finegold I, Fineman SM, Grabenhenrich L, Holgate S, Kuitunen M, Lau S, Maggi E, Martelli A, Matricardi P, Moretta L, Palmer D, Parronchi P, Pawankar R, Prescott S, Restani P, Rosenwasser L, Terracciano L, Scheurer S, Tripodi S, Vieths S, Von Berg A, Vultaggio A, Weber RW.

Curr Opin Allergy Clin Immunol. 2013 Mar;13 Suppl 1:S1-50. doi: 10.1097/ACI.0b013e32835e8b94. No abstract available.

PMID:
23377496
37.

Vav1 haploinsufficiency in a common variable immunodeficiency patient with defective T-cell function.

Capitani N, Ariani F, Amedei A, Pezzicoli A, Matucci A, Vultaggio A, Troilo A, Renieri A, Baldari CT, D' Elios MM.

Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):811-7.

PMID:
23058036
38.

Poly(I:C) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation.

Vultaggio A, Nencini F, Pratesi S, Petroni G, Romagnani S, Maggi E.

Allergy. 2012 Oct;67(10):1223-32. doi: 10.1111/j.1398-9995.2012.02876.x.. Epub 2012 Aug 7.

PMID:
22882449
39.

Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab.

Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, Alterini R, Rigacci L, Romagnani S, Maggi E.

Int Arch Allergy Immunol. 2012;159(3):321-6. doi: 10.1159/000336839. Epub 2012 Jun 22.

PMID:
22846615
40.

Multiorgan infiltration by CD8+ T cells and 1p;16p translocation in a patient with hypogammaglobulinemia and a reduced number of B cells.

Vultaggio A, Matucci A, D'Elios MM, Andreucci E, Giglio S, Annunziato F, Zupo S, Maggi E.

Int Arch Allergy Immunol. 2012;158(2):206-10. doi: 10.1159/000331117. Epub 2012 Jan 26.

PMID:
22286841
41.

Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.

Giannecchini S, Clausi V, Vultaggio A, Macera L, Maggi F, Martelli F, Azzi A, Maggi E, Matucci A.

J Neurovirol. 2012 Feb;18(1):55-61. doi: 10.1007/s13365-012-0078-1. Epub 2012 Jan 27.

PMID:
22281875
42.

T-cell responses during allergen-specific immunotherapy.

Maggi E, Vultaggio A, Matucci A.

Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):1-6. doi: 10.1097/ACI.0b013e32834ecc9a. Review.

PMID:
22157159
43.

Asthma: developments in targeted therapy.

Matucci A, Vultaggio A, Ridolo E, Maggi E, Canonica GW, Rossi O.

Expert Rev Clin Immunol. 2012 Jan;8(1):13-5. doi: 10.1586/eci.11.71. Review. No abstract available.

PMID:
22149334
44.

Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction.

Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E.

Intern Emerg Med. 2012 Sep;7 Suppl 2:S77-9. doi: 10.1007/s11739-011-0611-x. Epub 2011 May 5. No abstract available.

PMID:
21544533
45.

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management.

Vultaggio A, Maggi E, Matucci A.

Curr Opin Allergy Clin Immunol. 2011 Jun;11(3):262-8. doi: 10.1097/ACI.0b013e3283464bcd. Review.

PMID:
21460715
46.

The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines.

Vultaggio A, Nencini F, Pratesi S, Maggi L, Guarna A, Annunziato F, Romagnani S, Parronchi P, Maggi E.

J Immunol. 2011 Apr 15;186(8):4707-15. doi: 10.4049/jimmunol.1002398. Epub 2011 Mar 9.

47.

Genome-wide association study of serious blistering skin rash caused by drugs.

Shen Y, Nicoletti P, Floratos A, Pirmohamed M, Molokhia M, Geppetti P, Benemei S, Giomi B, Schena D, Vultaggio A, Stern R, Daly MJ, John S, Nelson MR, Pe'er I; International Serious Adverse Events Consortium (SAEC).

Pharmacogenomics J. 2012 Apr;12(2):96-104. doi: 10.1038/tpj.2010.84. Epub 2011 Jan 11.

PMID:
21221126
48.

Acute infusion reactions induced by monoclonal antibody therapy.

Maggi E, Vultaggio A, Matucci A.

Expert Rev Clin Immunol. 2011 Jan;7(1):55-63. doi: 10.1586/eci.10.90. Review.

PMID:
21162650
49.

Heart as the early main target of severe anaphylactic reactions: two case reports.

Matucci A, Vultaggio A, Fassio F, Rossi O, Maggi E.

Intern Emerg Med. 2011 Oct;6(5):467-9. doi: 10.1007/s11739-010-0482-6. Epub 2010 Nov 26. No abstract available.

PMID:
21110234
50.

Impaired TH2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defects.

Capitani N, Amedei A, Paccani SR, Matucci A, Vultaggio A, Del Prete G, Baldari CT, D'Elios MM.

J Allergy Clin Immunol. 2010 Sep;126(3):671-5. doi: 10.1016/j.jaci.2010.05.033. Epub 2010 Jul 16. No abstract available.

PMID:
20638113

Supplemental Content

Loading ...
Support Center